In a study conducted in 2016 by Marie Toft-Petersen et al., 22 (71%) of the 31 MDS patients examined presented with aberrant CLL-1 expression on CD34+/CD38- cells, regardless of the MDS subtype and IPSS risk group. This evidence concerns the gene CLEC12A and myelodysplastic syndrome.